Cryoport, World Courier Ink Logistics Deal for Gene Therapies
Cryoport dry shipper

Cryoport, Inc. announced that World Courier, a part of AmerisourceBergen, will integrate Cryoport’s full suite of temperature-controlled products into its global network. This integrated platform offers complete Chain of Compliance™ solutions for biopharmaceutical companies, ensuring full traceability of equipment, processes, and handling of cell and gene therapies while in transit.

This agreement between World Courier and Cryoport is for an initial three-year period with an evergreen provision.

This agreement will result in an offering of Cryoport’s Chain of ComplianceTM solutions to World Courier clients. Cryoport’s temperature-controlled offerings include Cryoport Express® shippers, use of the life sciences’ industry Cryoportal™ Logistics Management Platform, Smartpak II™ Condition Monitoring System and 24/7/365 logistics support to provide an integrated platform combining the strengths of both the Cryoport and World Courier systems to their respective biopharmaceutical clients, allowing each client to proactively minimize risks to their cell and gene therapies through the entire biopharma supply chain in order to maintain the efficacy of these valuable commodities.

These solutions will be offered through World Courier’s global network of more than 140 company-owned offices operating across 50 countries, as well as directly through Cryoport’s business development team.

Jerrell Shelton, Chief Executive Officer of Cryoport, Inc., said, “Chain of Compliance is unique to the life sciences industry, offering full traceability including the ability to collect and interpret comprehensive, in transit data to ensure a significantly more intelligent supply chain. We are proud that it will be integrated into World Courier’s current offerings and to provide a seamless platform within the precision medicine space. Working in conjunction with World Courier to provide complete visibility of the location and the most critical aspects of the conditions in which the therapies reside removes uncertainties around the efficacy of the therapies, providing peace of mind to doctors, manufacturers and patients. World Courier has played a key role in over 15,900 clinical trials and partnering with it will enable a greater number of pharmaceutical companies to access our solutions, not just in the U.S., but globally.”

Sam Herbert, President of World Courier, said, “We are pleased to offer Cryoport’s suite of temperature-controlled logistics solutions to our biopharmaceutical clients and mitigate risk within their commercial and clinical supply chains. This collaboration offers a more diverse range of reliable temperature-controlled solutions to our cell and gene therapy clients around the world.”